Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.26 USD | -3.50% | -16.06% | -43.62% |
Financials (USD)
Sales 2024 * | 370K | Sales 2025 * | 330K | Capitalization | 811M |
---|---|---|---|---|---|
Net income 2024 * | -230M | Net income 2025 * | -266M | EV / Sales 2024 * | 940 x |
Net cash position 2024 * | 462M | Net cash position 2025 * | 625M | EV / Sales 2025 * | 562 x |
P/E ratio 2024 * |
-3.43
x | P/E ratio 2025 * |
-3.24
x | Employees | 94 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.26% |
Latest transcript on Viridian Therapeutics, Inc.
1 day | -3.50% | ||
1 week | -16.06% | ||
Current month | -7.39% | ||
1 month | -13.82% | ||
3 months | -34.58% | ||
6 months | -24.71% | ||
Current year | -43.62% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 23-04-30 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 18-01-02 |
Tomas Kiselak
CHM | Chairman | 38 | 20-10-27 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 234 M€ | +7.45% | - | |
0.03% | 1,487 M€ | +9.06% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 12.28 | -3.31% | 138 688 |
24-05-22 | 12.7 | -1.40% | 665,816 |
24-05-21 | 12.88 | -4.80% | 801,612 |
24-05-20 | 13.53 | +0.59% | 1,310,446 |
24-05-17 | 13.45 | -8.07% | 1,106,910 |
Delayed Quote Nasdaq, May 23, 2024 at 11:06 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.62% | 811M | |
+63.00% | 62.59B | |
-2.08% | 41.18B | |
+44.47% | 40.29B | |
-8.29% | 27.9B | |
+12.15% | 26.21B | |
-21.85% | 19.09B | |
+5.41% | 13.08B | |
+25.32% | 12.26B | |
+28.33% | 12.05B |
- Stock Market
- Equities
- VRDN Stock